Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06693986 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Adenovirus (RGDCRAdCOX2F)

Name: Adenovirus (RGDCRAdCOX2F) — clinical trial record (NCT06693986)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 1

SponsorMasonic Cancer Center, University of Minnesota

Started2024-12-27

View on ClinicalTrials.gov ↗

Amendment history

2026-01-05

Study Status v3

Re-verified, no change to tracked fields

2024-12-27

Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v2

Trial statusNot Yet Recruiting→Recruiting

Start dateestimated 2025-02-01→confirmed 2024-12-27

Study sites0→1

2024-11-18

Study Status, Study Design v1

Re-verified, no change to tracked fields

2024-11-15

Original filing

Masonic Cancer Center, University of Minnesota

58 trials monitored

See 2 trials at risk

Pancreatic Cancer

1,634 trials monitored

See 90 trials at risk

This is a single center, Phase I dose finding study of a single direct tumor injection of an RGD modified conditionally replicative adenovirus (RGDCRAdcox2F) in persons with adenocarcinoma of the pancreas. The study is designed to determine the MTD of RGDCRAdCOX2F that corresponds to the maximum desired toxicity of ≤ 20%.

Trial Details

NCT Number	NCT06693986
Lead Sponsor	Masonic Cancer Center, University of Minnesota
Conditions	Adenocarcinoma of Pancreas
Enrollment	18 participants
Start Date	2024-12-27
Primary Completion	2028-10-15 (estimated)
Study Completion	2029-10-15 (estimated)
Updated on ClinicalTrials.gov	2026-01-07